Clinical Trials Logo

Acute Gouty Arthritis clinical trials

View clinical trials related to Acute Gouty Arthritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT06273813 Not yet recruiting - Acute Pain Clinical Trials

Treatment of Topical Ketorolac Gel in Acute Gouty Flare

Start date: February 2024
Phase: Phase 1
Study type: Interventional

This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac tromethamine injection, USP (15mg/mL) comparator in healthy volunteers, including an evaluation of safety, tolerability, and efficacy in gout participants with flare-up.

NCT ID: NCT03002974 Completed - Clinical trials for Acute Gouty Arthritis

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

anaGO
Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The patients will be divided in different treatment groups to compare anakinra to the available drug triamcinolone.

NCT ID: NCT02545777 Recruiting - Clinical trials for Acute Gouty Arthritis

The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending Turbid

Start date: May 2014
Phase: Phase 2
Study type: Interventional

This research is based on spleen trapped by dampness and turbid which is the pathogenesis of gouty arthritis.It uses effective prescription of Endocrinology of Dongzhimen Hospital.In this study, the investigators use multi-center randomized parallel controlled clinical trials.The treatment groups are afforded oral traditional Chinese medicine decoction-tonifying spleen and descending the turbid decoction as well as soaking and wet wrapping.The control groups are afforded diclofenac sodium enteric-coated tablets as a positive control drug.The outcome is evaluated by condition of symptoms remission,pain relief time, recurrence rate and laboratory index to determine the efficacy of internal and external treatment.And the research will provide optimized diagnosis and treatment program. The investigators hope this research will also get tonifying spleen and descending the turbid internal and external treatment for gouty arthritis effective clinical treatment.

NCT ID: NCT01593527 Withdrawn - Clinical trials for Acute Gouty Arthritis

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Start date: September 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult to treat gouty arthritis and moderate to severe CKD (stage 3 - 4).

NCT ID: NCT01431638 Completed - Clinical trials for Acute Gouty Arthritis

Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Start date: August 25, 2011
Phase: Phase 3
Study type: Interventional

This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.

NCT ID: NCT01356602 Completed - Clinical trials for Acute Gouty Arthritis

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Start date: May 2011
Phase: Phase 3
Study type: Interventional

This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.

NCT ID: NCT00170781 Completed - Clinical trials for Acute Gouty Arthritis

Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout

Start date: June 2005
Phase: Phase 4
Study type: Interventional

This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout. This is a multi-center, double-blind, randomized, parallel group study comparing a single daily dose of 400 mg lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms of efficacy